José Baselga - Concepedia

Author

José Baselga

Also Known As

Baselga, J., J BASELGA, J Baselga, J. Baselga, J.L. Baselga, Jos Baselga, Jose Baselga, José Baselga, Josè Baselga, José Baselga

368

Publications

73.8K

Citations

109

H-Index

141

Concepts

All Affiliations

Vall d'Hebron Hospital Universitari Memorial Sloan Kettering Cancer Center Universitat Autònoma de Barcelona Massachusetts General Hospital Hebron University

About

José Baselga is an author at Vall d'Hebron Hospital Universitari specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	54	104	21.5K
2	Health Sciences	18	28	2.5K
3	Natural Sciences	6	6	1.8K
4	Engineering	2	2	1.2K
5	Public Health	2	2	228

José Baselga

192

Publications

62.2K

Citations

H-Index

Page 1

	Year	Citations
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, New England Journal of Medicine	2001	11.4K
The landscape of somatic copy-number alteration across human cancers Rameen Beroukhim, Craig H. Mermel, Dale Porter, Nature Somatic VariantTumor HeterogeneityMedicinePathologySomatic Copy-number Alteration	2010	4K
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Sunil Verma, David Miles, Luca Gianni, New England Journal of Medicine	2012	3.7K
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Journal of Clinical Oncology	2003	2.9K
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, Javier Cortés, Sung‐Bae Kim, New England Journal of Medicine	2011	2.5K
Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma Aleksandar D. Kostic, Dirk Gevers, Chandra Sekhar Pedamallu, Genome Research Colorectal CarcinomaMicrobiota StructureMicrobial DiversityDysbiosisFusobacterium Sequences	2011	1.9K
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer Gϋnter von Minckwitz, Marion Procter, Evandro de Azambuja, New England Journal of Medicine	2017	1.4K
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Luca Gianni, W. Eiermann, Alexey Manikhas, The Lancet Noah TrialBreast OncologyOncologyClinical TrialsBreast Cancer	2010	1.2K
Sequence analysis of mutations and translocations across breast cancer subtypes Shantanu Banerji, Kristian Cibulskis, Claudia Rangel‐Escareño, Nature Recurrent MutationsBreast OncologyOncologyEngineeringSomatic Variant	2012	1.2K
Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol, Journal of Clinical Oncology	2007	1.1K

Page 1